List of Excipients in Branded Drug RANITIDINE 75

Generic Drugs Containing RANITIDINE 75

Company	Ingredient	NDC	Excipient
Major Pharmaceuticals	ranitidine	0904-6715	CELLULOSE, MICROCRYSTALLINE
Major Pharmaceuticals	ranitidine	0904-6715	D&C YELLOW NO. 10
Major Pharmaceuticals	ranitidine	0904-6715	FD&C BLUE NO. 2

What are the Most Frequently-Used Excipients in RANITIDINE 75?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 2

Ranitidine 75 Excipient Strategy, Patent Position, Regulatory Status, and Commercial Opportunities

Last updated: August 5, 2026

Ranitidine 75 mg has limited commercial potential in the United States because FDA-requested withdrawals removed ranitidine products from the market over N-nitrosodimethylamine (NDMA) contamination and formation concerns. The principal opportunity is outside the U.S., subject to national authorization and validated controls for nitrosamine risk. A viable product strategy would prioritize low-moisture excipients, nitrite-controlled raw materials, protective packaging, stability-indicating testing, and a formulation dossier that demonstrates acceptable NDMA levels throughout shelf life.

The molecule has no meaningful biosimilar issue because ranitidine is a small-molecule drug. Its legacy composition and use patents are expired or commercially weak. Current value would come from regulatory execution, manufacturing controls, geographic market selection, and differentiated delivery formats rather than conventional patent exclusivity.

What is the FDA status of ranitidine 75 mg?

FDA requested the withdrawal of all prescription and over-the-counter ranitidine products from the U.S. market on April 1, 2020. The agency concluded that NDMA levels in some ranitidine products could increase over time, particularly when products were stored at temperatures above room temperature. FDA stated that consumers should stop using ranitidine products and use alternative medicines where appropriate.[1]

Regulatory item	Status
U.S. OTC ranitidine 75 mg	Withdrawn from market
U.S. prescription ranitidine	Withdrawn from market
FDA approved ranitidine product currently marketed in the U.S.	None identified by FDA after the 2020 withdrawal
Original indication	Short-term treatment of heartburn and acid-related disorders
Primary regulatory barrier	NDMA formation and control
Current U.S. commercial path	New or reformulated application would require FDA acceptance of the risk-control package

The 2020 action followed earlier recalls by manufacturers including Sanofi and withdrawal recommendations for ranitidine products in other jurisdictions. FDA had previously advised manufacturers to remove ranitidine products after laboratory testing detected NDMA and showed that levels could rise under certain storage conditions.[1]

A later FDA approval for Zantac 360 used famotidine, not ranitidine. That product does not restore ranitidine’s U.S. regulatory status and should not be treated as a ranitidine 75 mg commercial precedent.

What patents protect ranitidine 75 mg?

Ranitidine’s core composition-of-matter and original therapeutic patents are expired. The historic ranitidine patent estate supported the original Zantac franchise but does not provide a current blocking position for ordinary ranitidine hydrochloride 75 mg tablets.

Core compound patents

Ranitidine was developed by Glaxo, now part of GSK. The principal historical patent coverage related to:

• Ranitidine and pharmaceutically acceptable salts
• Histamine H2-receptor antagonist activity
• Therapeutic use in gastric-acid disorders
• Solid oral dosage forms
• Manufacturing routes and intermediates

The original compound protection dates to the late 1970s and early 1980s. Any U.S. patent term associated with the original ranitidine molecule has expired. The same applies to the commercial exclusivity that supported the branded Zantac launch.

Formulation and manufacturing patents

Later patents may have addressed tablet formulations, granulation, coatings, dissolution profiles, manufacturing processes, or specific dosage forms. Those patents are generally old and are unlikely to block a modern 75 mg generic tablet unless a product intentionally practices a still-valid jurisdiction-specific claim.

The relevant diligence question is not whether any historical ranitidine patent exists. It is whether a proposed formulation practices an unexpired claim in the target country. That analysis requires a live patent search by jurisdiction, assignee, legal status, and claim scope.

When did ranitidine lose exclusivity?

Ranitidine lost practical small-molecule exclusivity years before the 2020 withdrawal. Generic ranitidine products were widely marketed in the U.S. and other countries before the NDMA issue.

Event	Approximate timing
Ranitidine compound development and priority filings	Late 1970s
Original Zantac approvals and commercial launch	Early 1980s
Generic competition	1990s and later
OTC U.S. ranitidine availability	1990s
Global NDMA recalls and investigations	2019
FDA request for complete U.S. withdrawal	April 2020
Current U.S. branded ranitidine opportunity	Effectively closed without a new FDA-approved product

The commercial constraint is therefore regulatory, not patent expiration. A new entrant cannot rely on abbreviated generic competition alone if the reference product is no longer commercially available or if FDA requires a new safety package.

What excipients are suitable for a ranitidine 75 mg tablet?

The preferred excipient strategy is designed to minimize moisture, heat exposure, reactive impurities, and nitrite or nitrate contribution. Excipients should be selected through supplier qualification, impurity testing, forced-degradation studies, and finished-product stability testing.

Candidate excipient architecture

A conventional immediate-release tablet could contain:

Functional role	Candidate excipient classes	Key control issue
Diluent	Microcrystalline cellulose, anhydrous dibasic calcium phosphate, mannitol	Water content and compatibility
Binder	Povidone, low-substituted hydroxypropyl cellulose, pregelatinized starch	Nitrite impurities, moisture uptake
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Nitrite/nitrate profile and dissolution
Lubricant	Magnesium stearate, stearic acid	Avoid excessive hydrophobicity and dissolution delay
Glidant	Colloidal silicon dioxide	Moisture control and flow
Film coat	Hypromellose-based coating	Water activity during coating and drying
Colorant	Iron oxides or approved lake pigments	Regulatory acceptability and impurity profile

A dry granulation or direct-compression process may be preferable to aqueous wet granulation because it reduces water exposure. Wet granulation is not automatically excluded, but it increases the burden of demonstrating that processing, drying, residual moisture, and storage do not increase NDMA.

Nitrite and nitrate control

The formulation program should test each excipient lot for nitrite and nitrate contributions where technically justified. Particular attention should be given to excipients that can contain trace inorganic nitrite, nitrate, or reactive impurities. Supplier certificates alone are insufficient for a high-risk product. The manufacturer should establish:

• Excipient-specific acceptance limits
• Qualified supplier lists
• Lot-release testing or periodic verification
• Change-control procedures
• Storage conditions for excipients
• Data linking excipient variability to NDMA results

FDA’s nitrosamine guidance recommends risk assessment across active ingredients, excipients, manufacturing processes, packaging, and storage.[2]

Moisture and thermal control

The commercial formulation should target low water activity and a stable moisture profile rather than relying only on a nominal loss-on-drying specification. Development work should compare:

• Direct compression versus dry granulation
• Standard versus anhydrous diluents
• High- and low-moisture disintegrants
• Multiple coating systems
• Blister versus bottle packaging
• Room-temperature and accelerated storage
• Open-container and in-use stability

The drug product should be evaluated under long-term, accelerated, and stress conditions that reflect actual distribution environments. Testing should include NDMA at initial release and throughout shelf life.

What packaging best protects ranitidine 75 mg?

Packaging is a core part of the product design. A standard high-density polyethylene bottle with a conventional closure may not provide the same control as a high-barrier blister or desiccated unit-dose system.

Preferred packaging options

A risk-ranked packaging program could compare:

1. Aluminum-aluminum blister
2. High-barrier cold-form or polymer blister
3. HDPE bottle with induction seal and desiccant
4. Unit-dose sachet or pouch
5. Child-resistant high-barrier bottle

A unit-dose blister has commercial advantages because it limits repeated exposure to ambient humidity and heat after opening. Bottles may reduce packaging cost but require stronger in-use stability data and desiccant performance.

The label storage condition should reflect validated product data. A manufacturer should not use an unusually permissive storage statement if NDMA increases under realistic temperature excursions.

What formulations are protected or commercially differentiated for ranitidine 75 mg?

Legacy immediate-release tablets are difficult to differentiate through patent protection. Commercial differentiation is more likely through formulation performance and regulatory evidence.

Potential formulation concepts

Formulation concept	Commercial rationale	Main technical barrier
Immediate-release tablet	Lowest development complexity	Weak differentiation and NDMA burden
Unit-dose blister tablet	Better moisture control	Higher packaging cost
Chewable tablet	OTC convenience	Flavoring, saliva exposure, impurity assessment
Orally disintegrating tablet	Rapid administration	Greater excipient and moisture sensitivity
Effervescent product	Fast dissolution	Acid-base system may increase degradation risk
Powder or granule	Flexible dosing	Greater surface-area and moisture exposure
Combination acid-relief product	Consumer convenience	Compatibility and regulatory complexity

An effervescent or highly hygroscopic product is a poor initial strategy because it can increase moisture-related risk and complicate nitrosamine control. A film-coated, immediate-release tablet in a protective blister is more commercially defensible.

How strong is the ranitidine patent estate?

The patent estate is weak for ordinary ranitidine 75 mg. Its strongest historical assets are expired composition and use patents. New patentability would likely depend on a genuinely novel formulation, packaging system, manufacturing process, impurity-control method, or combination product.

Patent strength by asset category

Asset category	Current strength
Ranitidine molecule	Very weak; historical protection expired
75 mg dose	Weak; dose alone is generally insufficient
Conventional tablet	Weak unless tied to a novel, non-obvious composition
Film coating	Weak unless linked to unexpected stability or performance
Nitrosamine-control process	Potentially moderate, depending on claim scope and enablement
Packaging configuration	Potentially moderate but vulnerable to design-around
Stability specification	Limited patent value unless supported by a novel process or product
Combination product	Potentially stronger, subject to clinical and regulatory requirements
Manufacturing route	Potentially useful in selected jurisdictions

A patent strategy focused only on the presence of a particular excipient is unlikely to create durable protection. Stronger claims would connect the formulation, process, packaging, and measurable stability result in a way that is difficult to design around.

What is the Orange Book status of ranitidine 75 mg?

The Orange Book does not provide a commercially useful exclusivity barrier for a legacy ranitidine 75 mg product. FDA’s withdrawal of ranitidine products removed the U.S. market opportunity that generic applicants would ordinarily target.

An Orange Book review should distinguish among:

• Historical ranitidine NDAs
• Withdrawn products
• Listed patents that have expired
• Any product withdrawn for safety or commercial reasons
• Whether a listed drug remains available as a reference for an ANDA

A withdrawn reference product creates a regulatory pathway issue. A sponsor seeking to reintroduce ranitidine would need to determine whether FDA would accept an ANDA-based approach or require a new application supported by a broader safety and quality package. The NDMA history makes reliance on historical approval data commercially insufficient.

Are there Paragraph IV challenges to ranitidine 75 mg?

Historical generic ranitidine ANDAs likely generated ordinary patent certifications and Paragraph IV activity before the principal patents expired. Those challenges no longer create a current commercial opportunity because the relevant patent barriers are old and the U.S. ranitidine market was withdrawn for safety reasons.

The material litigation question now concerns NDMA-related liability and regulatory status, not patent invalidity. A new applicant would face greater exposure from product quality, failure-to-warn, and manufacturing-control allegations than from an Orange Book patent suit.

What litigation affects ranitidine commercial entry?

Ranitidine has been the subject of extensive product-liability litigation involving alleged cancer risks and NDMA exposure. In 2022, a federal multidistrict litigation judge excluded plaintiffs’ general-causation expert testimony in the federal proceedings, which materially affected the federal case structure.[3]

The litigation record does not eliminate commercial risk. A manufacturer entering a market where ranitidine remains authorized would still face:

• Product-liability claims
• Recall risk
• Regulatory inspection risk
• Consumer class actions
• Distributor indemnity claims
• Insurance and reserve requirements
• Reputational damage from any elevated NDMA result

Settlement agreements and case dismissals should be reviewed separately by jurisdiction and defendant. A settlement involving an originator or distributor does not automatically resolve claims against a new manufacturer.

What generic entry risks exist for ranitidine 75 mg?

The principal generic-entry risks are regulatory and technical.

Risk matrix

Risk	Probability	Commercial effect
FDA rejection of U.S. reintroduction	High	Eliminates U.S. launch
NDMA increase during shelf life	High impact	Recall, approval failure, liability
Excipient-lot variability	Medium to high	Batch failure or revalidation
Packaging underperformance	Medium	Shelf-life restriction
Market withdrawal in another country	Medium	Loss of regional sales
Weak demand after safety warnings	High	Low inventory turnover
Patent blocking by legacy rights	Low	Limited current concern
Litigation expense	High	Material fixed and variable cost
Competitor substitution by famotidine or PPIs	High	Reduces addressable market

The U.S. launch scenario is unattractive unless a sponsor has a clear regulatory route and unusually strong NDMA data. A non-U.S. launch could be more feasible, but only where the national authority continues to permit ranitidine and the product meets local nitrosamine requirements.

Which companies are challenging or replacing ranitidine?

Ranitidine has largely been replaced by other acid-suppression products rather than challenged through patent litigation.

Competitive class	Representative products or companies	Competitive effect
H2 antagonists	Famotidine products from multiple generic manufacturers	Closest pharmacologic substitute
Proton-pump inhibitors	Omeprazole, esomeprazole, lansoprazole manufacturers	Stronger acid suppression and broad OTC presence
Antacids	Calcium carbonate, magnesium hydroxide, aluminum hydroxide products	Rapid symptom relief
Combination products	Antacid plus alginate or simethicone products	Consumer-oriented alternatives

Famotidine has the strongest direct replacement position in the H2-antagonist segment. Omeprazole and other proton-pump inhibitors compete for recurring heartburn and gastroesophageal reflux treatment.

A ranitidine 75 mg product would need a clear reason for use, such as price, local availability, or a specific consumer preference. Historical brand recognition alone is unlikely to overcome safety concerns.

What licensing deals affect ranitidine 75 mg?

The historical commercial franchise was associated with Glaxo and later GSK through Zantac. No current licensing arrangement can be assumed to provide rights to market a new ranitidine 75 mg product.

A licensing transaction would need to address:

• Rights to historical formulation or manufacturing know-how
• Use of trademarks, if any
• Access to stability and impurity data
• Regulatory correspondence
• Product-liability allocation
• Indemnification for legacy claims
• Territory and channel restrictions
• Recall costs
• Rights to future formulation patents

Because the molecule is off-patent, a license is more likely to involve regulatory data, manufacturing technology, branding, or territory access than basic active-ingredient rights.

What geographic markets may support ranitidine 75 mg?

The commercial opportunity is jurisdiction-specific. FDA withdrawal does not automatically prohibit sales in every country, but many regulators adopted restrictions or suspensions after the NDMA findings.

A geographic screening model should rank markets by:

1. Whether ranitidine remains authorized
2. Whether the authority accepts new applications
3. Nitrosamine limits and testing requirements
4. OTC versus prescription classification
5. Local demand for H2 antagonists
6. Import and manufacturing requirements
7. Litigation exposure
8. Availability of famotidine and proton-pump inhibitors

The most defensible strategy is a staged launch in jurisdictions that expressly permit ranitidine and have a defined nitrosamine-control framework. Launching in a country with unresolved regulatory status creates inventory and recall risk.

How much revenue exposure does ranitidine 75 mg present?

Ranitidine has low prospective revenue value in the U.S. because the product was withdrawn and consumer substitution has already occurred. Historical Zantac revenue was substantial before genericization and the NDMA crisis, but those historical sales do not forecast a new entrant’s revenue.

Commercial model

Revenue driver	Assessment
U.S. OTC market	Not currently accessible through an ordinary generic launch
Non-U.S. OTC market	Selective and regulator-dependent
Hospital market	Limited; alternative acid-suppression products are available
Brand premium	Weak without a legally usable brand and extensive safety support
Manufacturing margin	Potentially attractive if supply is low-cost and testing is efficient
Development cost	High relative to ordinary off-patent tablet because of NDMA controls
Launch timing	Dependent on local regulatory review and stability data
Revenue durability	Vulnerable to regulatory changes and substitution

A low-cost formulation does not necessarily produce an attractive return. Analytical testing, accelerated stability programs, high-barrier packaging, supplier qualification, insurance, and legal reserves can materially increase total product cost.

What is the recommended excipient and commercial strategy?

The strongest strategy is a conservative, evidence-led immediate-release tablet rather than a complex delivery system.

Recommended product profile

• Ranitidine hydrochloride equivalent to 75 mg ranitidine
• Direct-compression or dry-granulation process
• Low-moisture excipient platform
• Qualified excipient suppliers with nitrite and nitrate controls
• Film coating with validated drying parameters
• High-barrier unit-dose blister
• Long-term and accelerated NDMA monitoring
• Stability data under temperature excursion conditions
• Country-specific regulatory filing before commercial manufacture

A secondary opportunity could involve a differentiated combination product, but that would require additional clinical, labeling, compatibility, and regulatory work. It would also increase patent and product-liability complexity.

Key Takeaways

• Ranitidine 75 mg has no meaningful remaining core patent exclusivity.
• FDA requested complete U.S. withdrawal in April 2020 because of NDMA concerns.
• The principal commercial barrier is regulatory acceptance, not patent infringement.
• A low-moisture, nitrite-controlled formulation in high-barrier packaging is the preferred technical approach.
• Direct compression or dry granulation is generally more attractive than aqueous wet granulation for risk control.
• Famotidine and proton-pump inhibitors have replaced ranitidine across much of the acid-suppression market.
• U.S. reintroduction presents high regulatory, litigation, and commercial risk.
• Non-U.S. opportunities depend on each country’s current authorization and nitrosamine requirements.
• New patent value would need to come from a novel formulation, manufacturing process, packaging system, or combination product.
• Revenue potential is selective and unlikely to justify development without a defined jurisdictional pathway and strong stability data.

FAQs About Ranitidine 75 mg Excipient and Commercial Strategy

Can ranitidine 75 mg be reformulated without nitrite-containing excipients?

A sponsor can reduce nitrite and nitrate contribution through excipient selection and supplier controls, but the finished product still requires analytical testing. Eliminating a deliberately added nitrite source does not prove that NDMA will remain controlled during storage.

Is famotidine a commercially better substitute for ranitidine 75 mg?

Yes, in most markets. Famotidine remains an established H2-antagonist alternative without ranitidine’s specific NDMA history, although it has its own regulatory, competitive, and patent considerations.

Would a ranitidine 75 mg blister pack create patent protection?

Packaging alone may support patent claims only if the configuration is novel, non-obvious, and adequately enabled. A blister pack would provide practical differentiation but does not automatically create enforceable exclusivity.

Can an old ranitidine ANDA be used to relaunch the product?

Not automatically. FDA’s withdrawal action and the NDMA findings create a regulatory issue beyond ordinary generic substitution. The sponsor would need an acceptable application pathway and data package addressing product quality and stability.

Is an orally disintegrating ranitidine 75 mg tablet commercially attractive?

It could offer convenience, but it creates additional moisture, flavoring, excipient, and stability challenges. Unless the product demonstrates a clear market advantage, a conventional film-coated tablet in protective unit-dose packaging is lower risk.

References

1. U.S. Food and Drug Administration. (2020, April 1). FDA requests removal of all ranitidine products (Zantac) from the market. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market

2. U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs

3. U.S. District Court for the Southern District of Florida. (2022). In re: Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924, Order on general causation expert testimony.

4. European Medicines Agency. (2020). EMA recommends suspension of all ranitidine medicines in the EU. https://www.ema.europa.eu/en/news/ema-recommends-suspension-all-ranitidine-medicines-eu

5. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm